Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLA1555 is a single-shot, live-attenuated chikungunya virus (CHIKV) vaccine candidate developed by Instituto Butantan in collaboration with Valneva SE. It is a technology transfer of Valneva's approved vaccine VLA1553 (brand name IXCHIQ®), specifically adapted for local lyophilization and packaging by Butantan for use in Brazil and other Latin American or low- and middle-income countries (LMICs). The vaccine works by eliciting a protective immune response against the chikungunya virus through the administration of a live-attenuated strain. It is currently under regulatory review by Brazil's ANVISA and is being evaluated in Phase 3b clinical trials, including studies on co-administration with the Butantan live-attenuated dengue vaccine (Butantan-DV).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VLA1555.